Last reviewed · How we verify
Buprenorphine Injectable Product
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce pain and opioid cravings while carrying lower overdose risk than full agonists.
Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce pain and opioid cravings while carrying lower overdose risk than full agonists. Used for Moderate to severe acute and chronic pain, Opioid use disorder maintenance treatment.
At a glance
| Generic name | Buprenorphine Injectable Product |
|---|---|
| Also known as | Sublocade®; prev. RBP-60000 |
| Sponsor | King's College London |
| Drug class | Partial mu-opioid receptor agonist |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Pain Management; Opioid Use Disorder |
| Phase | Phase 3 |
Mechanism of action
Buprenorphine acts as a partial agonist at the mu-opioid receptor, producing analgesia and euphoria at lower levels than full opioid agonists due to its ceiling effect on respiratory depression. This pharmacological profile makes it suitable for both pain management and opioid use disorder treatment, with reduced potential for abuse and overdose compared to full mu-opioid agonists.
Approved indications
- Moderate to severe acute and chronic pain
- Opioid use disorder maintenance treatment
Common side effects
- Headache
- Nausea
- Dizziness
- Constipation
- Injection site reactions
- Respiratory depression
Key clinical trials
- Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections (PHASE2)
- INDV-6001 Multiple-Dose Pharmacokinetic Study (PHASE2)
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
- Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation (PHASE4)
- A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use (EARLY_PHASE1)
- Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial (PHASE4)
- Combined Injectable Treatment for HIV and OUD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |